Dosis de enoxaparina asociada a disminución de riesgo de muerte en COVID-19

BACKGROUND: In December 2019, an outbreak of COVID-19 was reported for the first time. This disease has caused millions of deaths worldwide. To date multiple drugs have been tried, without finding an effective treatment yet. OBJECTIVE: To describe the evolution and the pharmacological treatment used in patients hospitalized due to COVID-19. MATERIAL AND METHODS: Observational study in 200 patients hospitalized due to COVID-19 in a regional hospital of Acapulco who were admitted between March and July 2020. The characteristics, pharmacological treatment and evolution of the patients were identified. Univariate, bivariate and multivariate analyses were performed. RESULTS: 60% of the patients were male, 83% had at least one comorbidity, 56% died. The most used drug was enoxaparin, of which receiving a 60 mg dose was associated with a lower risk of death, compared to receiving 40 mg. Having received hydroxychloroquine, methylprednisolone, moxifloxacin and being 60 years or older was associated with a higher risk of progressing to death. CONCLUSIONS: There was a high mortality. The most used drug was enoxaparin, of which using doses of 60 mg reduced the risk of death.